FWD-F01

FWD-F01 is an investigational small molecule agonist of the Stimulator of Interferon Genes (STING) protein, developed by Shenzhen Forward Pharmaceuticals. It is designed to activate the cGAS-STING signaling pathway, a critical component of the innate immune system that detects cytosolic DNA. By binding to and activating STING, FWD-F01 triggers the production of Type I interferons (such as IFN-beta) and various pro-inflammatory cytokines. This immune activation is intended to enhance the recruitment, maturation, and activity of dendritic cells and cytotoxic T lymphocytes within the tumor microenvironment, thereby promoting a robust anti-tumor immune response. The drug is primarily being developed for the treatment of advanced or metastatic solid tumors, either as a monotherapy or in combination with other immunotherapeutic agents.